Phase 2 Safety and Efficacy Data To Be Presented on Provectus Pharmaceuticals Inc.’ PV-10 at 7th International Melanoma Research Congress on November 4, 2010

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, whose agenda can be found at:

MORE ON THIS TOPIC